WO2002086101A3 - Core-glycosylated hcv envelope proteins - Google Patents
Core-glycosylated hcv envelope proteins Download PDFInfo
- Publication number
- WO2002086101A3 WO2002086101A3 PCT/BE2002/000064 BE0200064W WO02086101A3 WO 2002086101 A3 WO2002086101 A3 WO 2002086101A3 BE 0200064 W BE0200064 W BE 0200064W WO 02086101 A3 WO02086101 A3 WO 02086101A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- envelope proteins
- hcv envelope
- glycosylated
- core
- oligomannoses
- Prior art date
Links
- 101710091045 Envelope protein Proteins 0.000 title abstract 5
- 101710188315 Protein X Proteins 0.000 title abstract 5
- 102100021696 Syncytin-1 Human genes 0.000 title abstract 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 abstract 3
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 2
- 230000004988 N-glycosylation Effects 0.000 abstract 1
- 241000235648 Pichia Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000002704 mannoses Chemical class 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24223—Virus like particles [VLP]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR0209034-1A BR0209034A (en) | 2001-04-24 | 2002-04-24 | Glycosylated hcv wrap proteins in the nucleus |
KR1020037013778A KR100950104B1 (en) | 2001-04-24 | 2002-04-24 | Core-glycosylated HCV envelope proteins |
AU2002257392A AU2002257392B2 (en) | 2001-04-24 | 2002-04-24 | Core-glycosylated hcv envelope proteins |
NZ529324A NZ529324A (en) | 2001-04-24 | 2002-04-24 | Core-glycosylated HCV envelope proteins made in yeast cells |
HU0303924A HUP0303924A2 (en) | 2001-04-24 | 2002-04-24 | Core-glycosylated hcv envelope proteins |
MXPA03009632A MXPA03009632A (en) | 2001-04-24 | 2002-04-24 | Core-glycosylated hcv envelope proteins. |
EP02727059A EP1417298A2 (en) | 2001-04-24 | 2002-04-24 | Core-glycosylated hcv envelope proteins |
CA002443781A CA2443781A1 (en) | 2001-04-24 | 2002-04-24 | Core-glycosylated hcv envelope proteins |
IL15842202A IL158422A0 (en) | 2001-04-24 | 2002-04-24 | Core-glycosylated hcv envelope proteins |
JP2002583616A JP4173741B2 (en) | 2001-04-24 | 2002-04-24 | Core glycosylated HCV envelope protein |
SK1314-2003A SK13142003A3 (en) | 2001-04-24 | 2002-04-24 | Core-glycosylated HCV envelope proteins |
HR20030946A HRP20030946A2 (en) | 2001-04-24 | 2003-11-20 | Core-glycosylated hcv envelope proteins |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01870088 | 2001-04-24 | ||
EP01870088.0 | 2001-04-24 | ||
US30560401P | 2001-07-17 | 2001-07-17 | |
US60/305,604 | 2001-07-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002086101A2 WO2002086101A2 (en) | 2002-10-31 |
WO2002086101A3 true WO2002086101A3 (en) | 2004-02-19 |
Family
ID=34072546
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BE2002/000063 WO2002086100A2 (en) | 2001-04-24 | 2002-04-24 | Expression of core-glycosylated hcv envelope proteins in yeast |
PCT/BE2002/000062 WO2002085932A2 (en) | 2001-04-24 | 2002-04-24 | Constructs and methods for expression of recombinant hcv envelope proteins |
PCT/BE2002/000064 WO2002086101A2 (en) | 2001-04-24 | 2002-04-24 | Core-glycosylated hcv envelope proteins |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BE2002/000063 WO2002086100A2 (en) | 2001-04-24 | 2002-04-24 | Expression of core-glycosylated hcv envelope proteins in yeast |
PCT/BE2002/000062 WO2002085932A2 (en) | 2001-04-24 | 2002-04-24 | Constructs and methods for expression of recombinant hcv envelope proteins |
Country Status (20)
Country | Link |
---|---|
US (3) | US7238356B2 (en) |
EP (3) | EP1414942A2 (en) |
JP (2) | JP4261195B2 (en) |
KR (1) | KR100950104B1 (en) |
CN (1) | CN1636050A (en) |
AR (3) | AR035869A1 (en) |
AU (3) | AU2002308449B2 (en) |
BR (2) | BR0209034A (en) |
CA (3) | CA2443781A1 (en) |
CZ (1) | CZ20032853A3 (en) |
HU (1) | HUP0303924A2 (en) |
MX (2) | MXPA03009626A (en) |
NZ (2) | NZ529324A (en) |
OA (1) | OA13092A (en) |
PL (1) | PL366621A1 (en) |
RU (1) | RU2274643C2 (en) |
SK (1) | SK13142003A3 (en) |
WO (3) | WO2002086100A2 (en) |
YU (1) | YU84103A (en) |
ZA (3) | ZA200308272B (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040185061A1 (en) * | 1994-07-29 | 2004-09-23 | Innogenetics N.V. | Redox reversible HCV proteins with native-like conformation |
EP1414942A2 (en) * | 2001-04-24 | 2004-05-06 | Innogenetics N.V. | Expression of core-glycosylated hcv envelope proteins in yeast |
DE10143490C2 (en) * | 2001-09-05 | 2003-12-11 | Gsf Forschungszentrum Umwelt | Recombinant MVA with the ability to express HCV structural antigens |
CA2504711A1 (en) * | 2002-11-08 | 2004-05-21 | Innogenetics N.V. | Hcv vaccine compositions comprising e1 and ns3 peptides |
US7439042B2 (en) * | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
JP4371739B2 (en) * | 2003-09-02 | 2009-11-25 | 株式会社東芝 | Electronic device having serial ATA interface and power saving method of serial ATA bus |
EP1602664A1 (en) * | 2004-03-08 | 2005-12-07 | Innogenetics N.V. | HCV E1 comprising specific disulfide bridges |
EP1574517A1 (en) | 2004-03-09 | 2005-09-14 | Innogenetics N.V. | HCV E1 comprising specific disulfide bridges |
JP4885476B2 (en) * | 2004-05-21 | 2012-02-29 | 株式会社日本触媒 | Method for introducing protein and / or peptide into cell |
SG156652A1 (en) * | 2004-10-18 | 2009-11-26 | Globeimmune Inc | Yeast-based therapeutic for chronic hepatitis c infection |
AU2011254055B2 (en) * | 2004-10-18 | 2012-12-20 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
US20060234360A1 (en) * | 2005-04-13 | 2006-10-19 | Paola Branduardi | Ascorbic acid production from D-glucose in yeast |
US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
US9216212B2 (en) | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
PE20070796A1 (en) * | 2005-10-24 | 2007-08-15 | Wyeth Corp | PROTEIN PRODUCTION METHOD USING ANTI-SENESCENCE COMPOUNDS |
WO2007136865A2 (en) * | 2006-05-19 | 2007-11-29 | Glycofi, Inc | Recombinant vectors |
AU2015234338C1 (en) * | 2006-07-28 | 2017-07-20 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
CN101563362B (en) * | 2006-08-25 | 2015-02-11 | 麦克法兰布奈特医疗研究与公共健康研究所有限公司 | Recombinant HCV E2 glycoprotein |
US8728489B2 (en) | 2008-09-19 | 2014-05-20 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis C virus infection |
US8580270B2 (en) | 2008-09-30 | 2013-11-12 | University Of Massachusetts | Respiratory synctial virus (RSV) sequences for protein expression and vaccines |
US20100104555A1 (en) * | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | HCV neutralizing epitopes |
DE102009044224A1 (en) * | 2009-10-09 | 2011-04-28 | PomBio Tech GmbH Starterzentrum der Universität des Saarlandes Campus Geb. A1-1 | Method for production of HCV virus-like particles |
UA118537C2 (en) | 2010-12-22 | 2019-02-11 | Байєр Інтеллектуал Проперті Гмбх | Enhanced immune response in bovine species |
US20140155469A1 (en) | 2011-04-19 | 2014-06-05 | The Research Foundation Of State University Of New York | Adeno-associated-virus rep sequences, vectors and viruses |
WO2012152823A1 (en) | 2011-05-09 | 2012-11-15 | Ablynx Nv | Method for the production of immunoglobulin single variable domains |
US10155950B2 (en) * | 2014-02-28 | 2018-12-18 | Bayer Animal Health Gmbh | Immunostimulatory plasmids |
EP3374500A1 (en) * | 2015-11-13 | 2018-09-19 | Mammedov, Tarlan | Production of in vivo n-deglycosylated recombinant proteins by co-expression with endo h |
DK3184642T3 (en) * | 2015-12-22 | 2019-08-12 | Bisy E U | yeast |
WO2018055535A2 (en) | 2016-09-21 | 2018-03-29 | The Governors Of The University Of Alberta | Hepatitis c virus immunogenic compositions and methods of use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996004385A2 (en) * | 1994-07-29 | 1996-02-15 | Innogenetics N.V. | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
WO1999054735A1 (en) * | 1998-04-17 | 1999-10-28 | Innogenetics N.V. | Improved immunodiagnostic assays using reducing agents |
WO1999067285A1 (en) * | 1998-06-24 | 1999-12-29 | Innogenetics N.V. | Particles of hcv envelope proteins: use for vaccination |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4395395A (en) * | 1979-05-21 | 1983-07-26 | The United States Of America As Represented By The Department Of Health And Human Services | Detection of non-A, non-B hepatitis associated antigen |
EP0288198A3 (en) | 1987-04-20 | 1989-03-29 | Takeda Chemical Industries, Ltd. | Production of peptide |
US5135854A (en) * | 1987-10-29 | 1992-08-04 | Zymogenetics, Inc. | Methods of regulating protein glycosylation |
US5683864A (en) * | 1987-11-18 | 1997-11-04 | Chiron Corporation | Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies |
US5350671A (en) * | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
US5698390A (en) * | 1987-11-18 | 1997-12-16 | Chiron Corporation | Hepatitis C immunoassays |
JP2791418B2 (en) * | 1987-12-02 | 1998-08-27 | 株式会社ミドリ十字 | Method for producing heterologous protein, recombinant DNA, transformant |
NO177065C (en) * | 1988-09-26 | 1995-07-12 | Labofina Sa | Process for the preparation of enzymatically active human lysozyme |
US5747239A (en) * | 1990-02-16 | 1998-05-05 | United Biomedical, Inc. | Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines |
US6312889B1 (en) * | 1990-04-04 | 2001-11-06 | Chiron Corporation | Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies |
WO1992001800A1 (en) * | 1990-07-20 | 1992-02-06 | Chiron Corporation | Method for integrative transformation of yeast using dispersed repetitive elements |
CA2047792C (en) | 1990-07-26 | 2002-07-02 | Chang Y. Wang | Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines |
HU227547B1 (en) | 1991-06-24 | 2011-08-29 | Novartis Vaccines & Diagnostic | Hepatitis c virus (hcv) polypeptides |
AU4659993A (en) | 1992-07-07 | 1994-01-31 | Merck & Co., Inc. | Vaccine comprising mixed pres1+pres2+s and core particle |
EP0979867A3 (en) | 1993-11-04 | 2007-06-13 | Innogenetics N.V. | Immunodominant human T-cell epitopes of hepatitis C virus |
ZA9610456B (en) * | 1995-12-20 | 1997-06-20 | Novo Nordisk As | N-terminally extended proteins expressed in yeast |
US5935824A (en) * | 1996-01-31 | 1999-08-10 | Technologene, Inc. | Protein expression system |
WO1998028429A1 (en) * | 1996-12-20 | 1998-07-02 | Novo Nordisk A/S | N-terminally extended proteins expressed in yeast |
WO1999024466A2 (en) | 1997-11-06 | 1999-05-20 | Innogenetics N.V. | Multi-mer peptides derived from hepatitis c virus envelope proteins for diagnostic use and vaccination purposes |
EP1049790A1 (en) * | 1998-01-23 | 2000-11-08 | Novo Nordisk A/S | Process for making desired polypeptides in yeast |
CZ20021819A3 (en) | 1999-10-27 | 2003-06-18 | Innogenetics N. V. | Oxidizing-reducing reversible HCV proteins with conformation similar to native proteins |
MXPA02008886A (en) | 2001-01-11 | 2003-04-25 | Innogenetics Nv | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use. |
EP1414942A2 (en) * | 2001-04-24 | 2004-05-06 | Innogenetics N.V. | Expression of core-glycosylated hcv envelope proteins in yeast |
JP2005516939A (en) | 2001-12-18 | 2005-06-09 | イノジェネティックス・ナムローゼ・フェンノートシャップ | Purified hepatitis C virus coat protein for diagnostic and therapeutic uses |
CA2504711A1 (en) * | 2002-11-08 | 2004-05-21 | Innogenetics N.V. | Hcv vaccine compositions comprising e1 and ns3 peptides |
-
2002
- 2002-04-24 EP EP02721875A patent/EP1414942A2/en not_active Withdrawn
- 2002-04-24 AR ARP020101495A patent/AR035869A1/en unknown
- 2002-04-24 JP JP2002583615A patent/JP4261195B2/en not_active Expired - Fee Related
- 2002-04-24 SK SK1314-2003A patent/SK13142003A3/en unknown
- 2002-04-24 CN CNA028126076A patent/CN1636050A/en active Pending
- 2002-04-24 NZ NZ529324A patent/NZ529324A/en unknown
- 2002-04-24 NZ NZ529019A patent/NZ529019A/en unknown
- 2002-04-24 RU RU2003130955/13A patent/RU2274643C2/en not_active IP Right Cessation
- 2002-04-24 AR ARP020101493A patent/AR035867A1/en unknown
- 2002-04-24 CA CA002443781A patent/CA2443781A1/en not_active Abandoned
- 2002-04-24 EP EP02727059A patent/EP1417298A2/en not_active Withdrawn
- 2002-04-24 MX MXPA03009626A patent/MXPA03009626A/en not_active Application Discontinuation
- 2002-04-24 CA CA002443740A patent/CA2443740A1/en not_active Abandoned
- 2002-04-24 CZ CZ20032853A patent/CZ20032853A3/en unknown
- 2002-04-24 US US10/128,590 patent/US7238356B2/en not_active Expired - Fee Related
- 2002-04-24 WO PCT/BE2002/000063 patent/WO2002086100A2/en active Application Filing
- 2002-04-24 HU HU0303924A patent/HUP0303924A2/en unknown
- 2002-04-24 OA OA1200500194A patent/OA13092A/en unknown
- 2002-04-24 PL PL02366621A patent/PL366621A1/en not_active Application Discontinuation
- 2002-04-24 BR BR0209034-1A patent/BR0209034A/en not_active IP Right Cessation
- 2002-04-24 MX MXPA03009632A patent/MXPA03009632A/en not_active Application Discontinuation
- 2002-04-24 AR ARP020101494A patent/AR035868A1/en unknown
- 2002-04-24 BR BR0209033-3A patent/BR0209033A/en not_active IP Right Cessation
- 2002-04-24 KR KR1020037013778A patent/KR100950104B1/en not_active IP Right Cessation
- 2002-04-24 AU AU2002308449A patent/AU2002308449B2/en not_active Ceased
- 2002-04-24 US US10/128,578 patent/US7048930B2/en not_active Expired - Fee Related
- 2002-04-24 WO PCT/BE2002/000062 patent/WO2002085932A2/en active IP Right Grant
- 2002-04-24 WO PCT/BE2002/000064 patent/WO2002086101A2/en active IP Right Grant
- 2002-04-24 AU AU2002257392A patent/AU2002257392B2/en not_active Ceased
- 2002-04-24 EP EP02764023A patent/EP1381671A2/en not_active Withdrawn
- 2002-04-24 YU YU84103A patent/YU84103A/en unknown
- 2002-04-24 JP JP2002583616A patent/JP4173741B2/en not_active Expired - Fee Related
- 2002-04-24 US US10/128,587 patent/US7314925B2/en not_active Expired - Fee Related
- 2002-04-24 CA CA002444006A patent/CA2444006A1/en not_active Abandoned
- 2002-04-24 AU AU2002252856A patent/AU2002252856A1/en not_active Abandoned
-
2003
- 2003-10-23 ZA ZA200308272A patent/ZA200308272B/en unknown
- 2003-10-23 ZA ZA200308277A patent/ZA200308277B/en unknown
- 2003-10-23 ZA ZA200308274A patent/ZA200308274B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996004385A2 (en) * | 1994-07-29 | 1996-02-15 | Innogenetics N.V. | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
WO1999054735A1 (en) * | 1998-04-17 | 1999-10-28 | Innogenetics N.V. | Improved immunodiagnostic assays using reducing agents |
WO1999067285A1 (en) * | 1998-06-24 | 1999-12-29 | Innogenetics N.V. | Particles of hcv envelope proteins: use for vaccination |
Non-Patent Citations (3)
Title |
---|
HELENIUS ARI: "How N-linked oligosaccharides affect glycoprotein folding in the endoplasmic reticulum.", MOLECULAR BIOLOGY OF THE CELL, vol. 5, no. 3, 1994, pages 253 - 265, XP009008191, ISSN: 1059-1524 * |
KURODA S ET AL: "HEPATITIS B VIRUS ENVELOPE L PROTEIN PARTICLES SYNTHESIS AND ASSEMBLY IN SACCHAROMYCES CEREVISIAE, PURIFICATION AND CHARACTERIZATION", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 267, no. 3, 25 January 1992 (1992-01-25), pages 1953 - 1961, XP002937464, ISSN: 0021-9258 * |
KURODA S ET AL: "SACCHAROMYCES CEREVISIAE CAN RELEASE HEPATITIS B VIRUS SURFACE ANTIGEN (HBSAG) PARTICLES INTO THE MEDIUM BY ITS SECRETORY APPARATUS", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 40, no. 2/3, 1993, pages 333 - 340, XP009000216, ISSN: 0175-7598 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002086101A3 (en) | Core-glycosylated hcv envelope proteins | |
EP2412242A3 (en) | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof | |
EP0948905A3 (en) | Enzyme preparations comprising transglutaminase and process for producing noodles | |
AU5779400A (en) | Process for the preparation of 3,3-dimethylbutanal | |
TR200000175T2 (en) | Preparation of erythropoietin with endogenic gene activation. | |
EP1461079B8 (en) | Human immunodeficiency virus envelope glycoprotein mutants and uses thereof | |
EP1408117A4 (en) | Glycoprotein and process for producing the same | |
AU2002324532A1 (en) | Yeast expression systems, methods of producing polypeptides in yeast, and compositions relating to same | |
EP0908520A3 (en) | Maleate isomerase gene | |
WO2002049441A3 (en) | Liquid yeast compositions | |
EP1409694A4 (en) | Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof | |
WO1998043936A3 (en) | Improved methods of manufacturing betulinic acid | |
HUP9600325A1 (en) | Dna sequence coding for delta-7-red protein of a. thaliana having a delta-5,7 sterol, delta-7 reductase activity, delta-7-red protein, production process, strains of transformed yeasts and their uses | |
WO2000039306A3 (en) | Detergent compositions comprising phenol oxidizing enzymes from fungi | |
WO2003020876A3 (en) | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof | |
WO2001034951A3 (en) | A gas sensor terminal assembly and method of producing same | |
WO2000005389A3 (en) | Production of proteins | |
AU5798500A (en) | Beam structure and method for producing such structures | |
CA2473384A1 (en) | Composite iso-stress sail structure and method for making | |
WO1999019352A3 (en) | Methods and compositions to alter the cell surface expression of phosphatidylserine and other clot-promoting plasma membrane phospholipids | |
WO1999006011A3 (en) | Shellac-containing cosmetic product | |
WO1996033277A3 (en) | Recombinant preduodenal lipases and polypeptide derivatives produced by plants, processes for obtaining them and their uses | |
CA2416954A1 (en) | Method of preparing a compound concentrate and processing such a concentrate | |
WO1997005848A3 (en) | Fibreboard casket base and lid and method of manufacturing same | |
GR3026718T3 (en) | Multilayered pasta-type paste and method for producing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-841/03 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2443781 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 158422 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2003-2853 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002257392 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/009632 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13142003 Country of ref document: SK Ref document number: 1020037013778 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/08274 Country of ref document: ZA Ref document number: 200308274 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002583616 Country of ref document: JP Ref document number: 1200300949 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1755/DELNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 529324 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002727059 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20030946A Country of ref document: HR |
|
ENP | Entry into the national phase |
Ref document number: 10837302 Country of ref document: BG Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028126076 Country of ref document: CN |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2002727059 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-2853 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 529324 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 529324 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002257392 Country of ref document: AU |